Arda therapeutics pioneers new approach to combat chronic diseases and ageing
Longevity Technology - 10-Oct-2024Targeted cell depletion offers a transformative strategy to treat diseases at their root
Join the club for FREE to access the whole archive and other member benefits.
Principal Investigator at Calico
Adam has studied aspects of the biology of aging throughout his career. His graduate work with Judy Campisi at the University of California at Berkeley and the Buck Institute focused on the regulation of inflammatory networks during cellular senescence. He then did postdoctoral work with Steven Artandi at Stanford University, where he developed high content screening methods to identify regulators of telomerase.
Citations: https://scholar.google.com/citations?user=zZqpf2gAAAAJ&hl=en
Visit website: https://www.calicolabs.com/people/adam-freund-ph-d
See also: Calico - Combating aging and associated diseases. An Alphabet (Google) subsidiary.
Details last updated 04-Sep-2020
Targeted cell depletion offers a transformative strategy to treat diseases at their root
Tailoring strategies to eliminate bad cells in age-related diseases
More and more companies making greater and greater progress - 2021 could be an exciting year
Will be presenting a viable therapeutic strategy using IGF signaling at ARDD 2020